{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:40:05Z","timestamp":1749908405249,"version":"3.41.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13136-7","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:26:46Z","timestamp":1747657606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tourette syndrome: effects of acetyl-leucine in two individuals"],"prefix":"10.1007","volume":"272","author":[{"given":"Eva Maria","family":"Hofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Musil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennard","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina A.","family":"Schindlbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"3","key":"13136_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00787-021-01899-z","volume":"31","author":"V Roessner","year":"2022","unstructured":"Roessner V, Eichele H, Stern JS et al (2022) European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 31(3):425\u2013441. https:\/\/doi.org\/10.1007\/s00787-021-01899-z","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"13136_CR2","doi-asserted-by":"publisher","first-page":"fcaa148","DOI":"10.1093\/braincomms\/fcaa148","volume":"3","author":"E Kaya","year":"2020","unstructured":"Kaya E, Smith DA, Smith C et al (2020) Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun 3(1):fcaa148. https:\/\/doi.org\/10.1093\/braincomms\/fcaa148","journal-title":"Brain Commun"},{"issue":"5","key":"13136_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2310151","volume":"390","author":"T Bremova-Ertl","year":"2024","unstructured":"Bremova-Ertl T, Ramaswami U, Brands M et al (2024) Trial of N-Acetyl-l-Leucine in niemann pick disease type C. N Engl J Med 390(5):421\u2013431. https:\/\/doi.org\/10.1056\/NEJMoa2310151. (PMID: 38294974)","journal-title":"N Engl J Med"},{"issue":"10","key":"13136_CR4","doi-asserted-by":"publisher","first-page":"e1072","DOI":"10.1212\/WNL.0000000000201660","volume":"100","author":"K Martakis","year":"2023","unstructured":"Martakis K, Claassen J, Gascon-Bayarri J et al (2023) Efficacy and safety of N-Acetyl-l-Leucine in children and adults with GM2 gangliosidoses. Neurology 100(10):e1072\u2013e1083. https:\/\/doi.org\/10.1212\/WNL.0000000000201660","journal-title":"Neurology"},{"issue":"10","key":"13136_CR5","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1007\/s00415-013-7016-x","volume":"260","author":"M Strupp","year":"2013","unstructured":"Strupp M, Teufel J, Habs M et al (2013) Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 260(10):2556\u20132561. https:\/\/doi.org\/10.1007\/s00415-013-7016-x","journal-title":"J Neurol"},{"issue":"1","key":"13136_CR6","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1038\/s41467-024-51502-7","volume":"15","author":"WH Oertel","year":"2024","unstructured":"Oertel WH, Janzen A, Henrich MT et al (2024) Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern-case reports. Nat Commun 15(1):7619. https:\/\/doi.org\/10.1038\/s41467-024-51502-7","journal-title":"Nat Commun"},{"issue":"7","key":"13136_CR7","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s00415-021-10625-3","volume":"268","author":"T Fields","year":"2021","unstructured":"Fields T, Schoser B, Oertel W et al (2021) Acetyl-DL-leucine improves restless legs syndrome: a case report. J Neurol 268(7):2595\u20132596. https:\/\/doi.org\/10.1007\/s00415-021-10625-3","journal-title":"J Neurol"},{"issue":"4","key":"13136_CR8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/jcm9041050","volume":"9","author":"E Kaya","year":"2020","unstructured":"Kaya E, Smith DA, Smith C et al (2020) Beneficial effects of Acetyl-DL-Leucine (ADLL) in a mouse model of sandhoff disease. J Clin Med. 9(4):1050. https:\/\/doi.org\/10.3390\/jcm9041050","journal-title":"J Clin Med."},{"issue":"2","key":"13136_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cct.2013.08.012","volume":"36","author":"S Jeon","year":"2013","unstructured":"Jeon S, Walkup JT, Woods DW, Peterson A, Piacentini J, Wilhelm S, Katsovich L, McGuire JF, Dziura J, Scahill L (2013) Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials 36(2):414\u2013420. https:\/\/doi.org\/10.1016\/j.cct.2013.08.012","journal-title":"Contemp Clin Trials"},{"key":"13136_CR10","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2025.0036","author":"JF McGuire","year":"2025","unstructured":"McGuire JF, Karkanias GB, Bittman RM, Atkinson SD, Munschauer FE, Wanaski SP, Cunniff TM, Gilbert DL (2025) Determining clinically meaningful improvement in children and adolescents with tourette syndrome receiving pharmacotherapy. J Child Adolesc Psychopharmacol. https:\/\/doi.org\/10.1089\/cap.2025.0036","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"13136_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/mds.29714","volume":"39","author":"S Wang","year":"2024","unstructured":"Wang S, Xiong Z, Cui Y, Fan F, Zhang S, Jia R, Hu Y, Li L, Zhang X, Han F (2024) Placebo and nocebo responses in pharmacological trials of tic disorders: a meta-analysis. Mov Disord 39:585\u2013595. https:\/\/doi.org\/10.1002\/mds.29714","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13136-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:08Z","timestamp":1749907508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13136"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13136-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R. Musil is Assistant Editor of Frontiers in Psychiatry, Psychopharmacology Section. He has received financial research support from the EU (H2020 No. 754740), the Tourette Gesellschaft Deutschland e.V., Abide Therapeutics, B\u00f6hringer-Ingelheim, Emalex Biosciences, Lundbeck, NOEMA Pharma, Nuvelution TS Pharma Inc., Otsuka Pharmaceuticals and Therapix Biosciences. He has received speakers\u2019 honoraria from Otsuka Pharmaceuticals and Lundbeck. RM is a member of the advisory board of the Tourette Gesellschaft Deutschland e.V. and B\u00f6hringer-Ingelheim. M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker\u2019s honoraria from Abbott, Auris Medical, Biogen, Eisai, Gr\u00fcnenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He receives support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany. He distributes \u201cM-glasses\u201d and \u201cPositional vertigo App\u201d. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, IntraBio, Sensorion, Vifor and Vertify. He is an investor and patent- and shareholder in IntraBio. L. Strupp is a consultant of, and investor and shareholder in IntraBio. P. Falkai received research support\/honoraria for lectures or advisory activities from: Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter. He has received and is currently receiving grants from several national and international foundations and institutions, e.g. from the \u201cGerman Science Foundation\u201d, the \u201cGerman Ministry of Science\u201d and the \u201cGerman Ministry of Health\u201d. K. Schindlbeck is receiving funding from the Bavarian Gender Equality Grant (BGF) 2024. All other authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"408"}}